|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021665,
umls-concept:C0030705,
umls-concept:C0086045,
umls-concept:C0205318,
umls-concept:C0229671,
umls-concept:C0282460,
umls-concept:C0289313,
umls-concept:C0418981,
umls-concept:C0439858,
umls-concept:C0473169,
umls-concept:C1274040,
umls-concept:C1280500
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-4-19
|
|
pubmed:abstractText |
Current therapies for acromegaly are unsatisfactory for some patients. High-dose thiazolidinediones have been reported to reduce serum GH levels in animal models of acromegaly. The objective of the study was to evaluate the effect of increasing doses of rosiglitazone on serum GH and IGF-I concentrations in acromegalic patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1720-8386
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e43-51
|
|
pubmed:meshHeading |
pubmed-meshheading:20671417-Acromegaly,
pubmed-meshheading:20671417-Adult,
pubmed-meshheading:20671417-Animals,
pubmed-meshheading:20671417-Antineoplastic Agents, Hormonal,
pubmed-meshheading:20671417-Female,
pubmed-meshheading:20671417-Hep G2 Cells,
pubmed-meshheading:20671417-Human Growth Hormone,
pubmed-meshheading:20671417-Humans,
pubmed-meshheading:20671417-Hypoglycemic Agents,
pubmed-meshheading:20671417-Insulin-Like Growth Factor I,
pubmed-meshheading:20671417-Male,
pubmed-meshheading:20671417-Middle Aged,
pubmed-meshheading:20671417-Octreotide,
pubmed-meshheading:20671417-Pilot Projects,
pubmed-meshheading:20671417-Thiazolidinediones,
pubmed-meshheading:20671417-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.
|
|
pubmed:affiliation |
Department of Endocrinology and Metabolism, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy. fausto.bogazzi@med.unipi.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
